Related Experiment Video
Updated: Aug 7, 2026
09:00
Investigating Pain-Related Avoidance Behavior using a Robotic Arm-Reaching Paradigm
Published on: October 3, 2020
Current and future approaches to inhibitor management and aversion
Charles Hay1, Michael Recht, Manuel Carcao
1Manchester Royal Infirmary, Manchester, United Kingdom. haemophilia@man.ac.uk
Seminars in Thrombosis and Hemostasis
|June 29, 2006
Summary
Immune tolerance induction (ITI) is a key treatment for hemophilia A patients with inhibitors. Recombinant factor VIII (rFVIII) products show promise, and new strategies like gene therapy are being explored to prevent inhibitor development.
Area of Science:
- Hematology
- Immunology
- Genetics
Background:
- Inhibitors to factor VIII (FVIII) are a significant complication in hemophilia A treatment.
- Immune tolerance induction (ITI) is the standard approach to eliminate these inhibitors.
- ITI typically involves long-term exposure to FVIII or factor IX (FIX) replacement therapy.
Purpose of the Study:
- To review the effectiveness of ITI for hemophilia A patients with inhibitors.
- To discuss alternative and emerging strategies for inhibitor management and prevention.
Main Methods:
- Review of current literature on ITI protocols and outcomes.
- Analysis of data on plasma-derived versus recombinant FVIII products for ITI.
- Exploration of novel therapeutic approaches, including immunosuppressive agents and gene therapy.
Main Results:
- Recombinant FVIII (rFVIII) products appear as effective as plasma-derived products for ITI.
- Immunosuppressive therapy, such as rituximab, shows potential but requires further study in congenital hemophilia.
- Investigational strategies include modifying FVIII epitopes and gene therapy targeting specific FVIII domains.
Conclusions:
- ITI remains the cornerstone for managing FVIII inhibitors in hemophilia A.
- Recombinant products offer a viable alternative for ITI.
- Future research focuses on innovative methods to prevent inhibitor development and improve ITI efficacy.
Related Concept Videos
01:24Operant Conditioning Intervention
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
In operant conditioning, behaviors that are...
01:30Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.